This page shows the latest Amag news and features for those working in and with pharma, biotech and healthcare.
Meanwhile, another key driver of the deal is thought to be the potential to push sales of Lumara's drug using Amag's commercial base. ... Under the terms of the acquisition, Lumara will operate as a separate business within Amag reporting to the Amag's
As reported by Reuters, Amag's shares were down about 5 per cent following the recall announcement. ... Both Amag and Takeda are now investigating the Swiss batch of Rienso, while the introduction of new batches will depend on approval by Swiss health
Newron should receive a $2m termination fee from Biotie. The $179m merger between oncology company, Allos Therapeutics and AMAG Pharmaceuticals announced in July, was terminated when AMAG shareholders rejected the deal ... 2 ##. Allos Therapeutics/AMAG
One of the Amag investors, the hedge fund MSMB, strongly opposed the merger and made a bid of $381m for Amag. ... Retin-A and Renova. Launched. 345. Amag/Allos. Amag merges with Allos, pays $268m to Allos shareholders.
318. AMAG Pharmaceuticals/ Takeda. feraheme (ferumoxytol) - for iron deficiency anaemia.
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Acquisition - business unit. 1, 045. EndoCeutics/ AMAG Pharmaceuticals. Intraros (prasterone), non-oestrogen product for postmenopausal atrophic vaginitis (FDA approved), female sexual dysfunction (phase III).
500. Palatin Technologies. AMAG Pharmaceutical. Exclusive licence for N. America. Rekynda (bremelanotide) for sexual disorder p3.
1, 750. Lumara Health / Amag. Lumara Health / Perrigo. Company acquisition (excluding Perrigo products).
Amag is buying the remaining company for up to $1.025bn. It contains Makena, a progesterone injection with US orphan status to reduce the risk of preterm birth with annual sales
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
She joins Orchard from AMAG Pharmaceuticals, where she served as senior vice president, corporate affairs, directing the company’s communications, government relations and advocacy activities.
Zieziula brings over 30 years of pharmaceutical experience to the role, having held senior management positions at Amag Pharmaceuticals, Bristol Myers-Squibb, MSD and Roche, before joining Merck in 2015 as
Lee Allen joins from AMAG Pharmaceuticals. Dr Lee Allen has joined cancer-focused Spectrum Pharmaceuticals as chief medical officer. ... 2013. The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.